Glaukos Sets Terms for $75 Million IPO

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Glaukos Corporation, an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, announced today the launch of its initial public offering of 5,358,000 shares of its common stock. The initial public offering price is currently estimated to be between $13 and $15 per share. The underwriters for the offering will also have a 30-day option to purchase up to an additional 803,700 shares of Glaukos common stock. Glaukos’ common stock has been approved for listing on the New York Stock Exchange under the symbol “GKOS.”

J.P. Morgan, BofA Merrill Lynch and Goldman, Sachs & Co. are acting as joint book-running managers for the offering. William Blair and Cantor Fitzgerald & Co. are acting as co-managers for the offering.

This offering will be made only by means of a prospectus. A copy of the preliminary prospectus related to the offering may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Phone: (866) 803-9204; BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or email dg.prospectus_requests@baml.com; or Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, New York 10282, or by telephone at (866) 471-2526 or email at prospectus-ny@ny.email.gs.com.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of any offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

About Glaukos

Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. Glaukos launched iStent Trabecular Micro-Bypass Stent, the industry’s first Micro-Invasive Glaucoma Surgery (MIGS) device, in the United States in 2012. The company is based in Laguna Hills, CA.